论文部分内容阅读
目的:观察可必特联合博利康尼雾化吸入治疗支气管哮喘的疗效。方法:选取我院2011年1月～2012年6月住院的支气管哮喘合并感染患者80例,分为治疗组和对照组。2组均给予以抗炎、化痰、茶碱类、单用可必特或博利康尼等常规治疗,治疗组在常规治疗基础上给予可必特联合博利康尼雾化吸入。结果:治疗组显效率和总有效率分别与对照组比较,差异均有统计学意义(P<0.05)。结论:可必特联合博利康尼雾化吸入治疗支气管哮喘疗效显著,值得推广。
Objective: To observe the curative effect of bilobalib atomized inhalation for bronchial asthma. Methods: Eighty patients with bronchial asthma who were admitted to our hospital from January 2011 to June 2012 were selected and divided into treatment group and control group. The two groups were given anti-inflammatory, phlegm, theophylline alone may be special or Boli Kang Ni and other conventional treatment, the treatment group on the basis of conventional treatment may be given combination of Boli Kang Ni inhalation. Results: The effective rate and total effective rate in the treatment group were significantly different from those in the control group (P <0.05). Conclusion: It is worth to promote the combination of bilirubin and atomization inhalation of bronchial asthma for bronchial asthma.